GT
ALLO icon

Glenmede Trust’s Allogene Therapeutics ALLO Stock Holding History

Glenmede Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-150
Closed -$5K – 1232
2020
Q3 		$5K Hold
150
– – ﹤0.01% 2078
2020
Q2 		$6K Hold
150
– – ﹤0.01% 2012
2020
Q1 		$3K Hold
150
– – ﹤0.01% 2768
2019
Q4 		$3K Buy
+150
New +$4.13K ﹤0.01% 2768

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glenmede Trust's ALLO Position: Q4 2020 in Review

Glenmede Trust sold out of Allogene Therapeutics (ALLO) in Q4 2020, closing a stake of 150 shares — an estimated $5K sold.

Glenmede Trust first reported a position in ALLO in Q4 2019 and held it in 4 quarters. The position peaked at $6K in Q2 2020. 165 funds tracked by Wall St. Rank hold ALLO as of Q4 2020.

  • Glenmede Trust reported no remaining Allogene Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 150 Allogene Therapeutics shares in Q4 2020, an estimated $5K.
  • Glenmede Trust first reported a position in Allogene Therapeutics in Q4 2019 and held it in 4 quarters.
  • Glenmede Trust's Allogene Therapeutics position peaked at $6K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.